




## Supplemental Figure 1



## Supplemental Figure 2



Supplemental Figure 3





**Supp Table 1**

	COVID-19	
	ICU	Non-ICU
<b>Asthma</b>	3 (21)	3 (27)
<b>Autoimmune disease</b>	3 (21)	2 (18)
<b>Cancer</b>	1 (7)	3 (27)
<b>COPD</b>	4 (29)	3 (27)
<b>Coronary Artery Disease</b>	2 (14)	6 (55)
<b>Congestive Heart Failure</b>	3 (21)	5 (45)
<b>CKD without dialysis</b>	2 (14)	4 (36)
<b>CKD/ESRD with dialysis</b>	3 (21)	2 (18)
<b>Diabetes Mellitus</b>	4 (29)	4 (36)
<b>Hyperlipidemia</b>	4 (29)	5 (45)
<b>Hypertension</b>	6 (43)	5 (45)
<b>Immune suppression</b>	5 (36)	4 (36)

**Supplemental Table 2.**

Lymphocyte Monitoring	18+ Normal Range		Healthy		Covid-19+		Covid-19+ ICU		Covid-19+ Non ICU	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
Monocytes	3.1 - 11.3	5.86	0.30	5.78	0.45	4.06	0.37	7.82	0.62	
Lymphocytes	8.6 - 47.2	36.99	2.76	17.44	1.65	11.91	1.48	25.46	2.52	
CD3	60.3 - 90.6	73.30	3.01	70.94	1.54	68.33	1.98	74.61	2.50	
CD20	2.4 - 21.4	10.39	1.06	15.31	1.53	17.08	2.28	12.03	1.93	
CD3-CD16+ or CD56+	2.3 - 24.7	14.13	2.62	10.22	1.09	10.03	1.38	11.00	1.95	
%TBNK		97.82	0.38	96.47	0.44	95.43	0.69	97.64	0.34	
CD3+CD16+ or CD56+	0.3 - 7.9	5.73	0.88	5.75	0.59	5.20	0.89	6.84	0.75	
<b>T Cell Monitoring and Activation</b>										
CD3+/CD4+	28.3 - 69.4	46.52	2.65	46.08	1.61	47.63	2.35	42.89	2.10	
CD3+/CD8+	8.6 - 39.5	21.47	2.14	21.43	1.72	17.60	1.42	27.60	3.33	
CD3+/CD4-/CD8-	0.4 - 5	4.49	0.81	2.77	0.26	2.58	0.30	3.26	0.49	
CD3/alpha/beta	56 - 87.6	67.37	3.17	66.60	1.52	64.33	1.89	69.67	2.65	
CC3/gamma-delta	0.2 - 5.8	3.36	0.81	1.93	0.31	1.50	0.35	2.67	0.58	
DNT/alpha/beta	0.1 - 1.7	1.06	0.12	0.92	0.08	1.02	0.13	0.84	0.09	
DNT/gamma-delta	0.2 - 4.3	3.24	0.79	1.57	0.26	1.21	0.29	2.20	0.47	
CD3+/CD8+/CD57+	1.2 - 17.2	7.31	1.73	8.72	1.30	5.60	0.98	13.39	2.58	
CD3+/HLA-DR	1.0 - 9.6	1.35	0.25	3.31	0.37	3.21	0.31	3.35	0.84	
CD3+/CD25	11.2 - 53.9	12.20	1.20	13.67	0.54	14.05	0.82	12.76	0.60	
T4/T8 Ratio	0.71 - 4.3	2.50	0.25	2.80	0.29	3.25	0.44	2.04	0.30	
<b>T Cell Memory</b>										
CD3/CD4/CD45RO	9.9 - 37.7	26.70	1.77	32.43	1.98	29.27	2.92	35.82	2.61	
CD3/CD4/CD45RA	3.4 - 37.9	23.68	2.19	19.79	2.37	26.12	3.38	10.87	2.30	
CD3/CD8/CD45RO	1.0 - 8.3	6.71	1.00	5.02	0.67	3.41	0.58	7.39	1.28	
CD3/CD8/CD45RA	2.4 - 23	15.09	1.77	16.22	1.54	14.88	1.79	18.73	2.90	
CD4/CRTH2	0.2 - 3.29	1.31	0.14	1.46	0.12	1.41	0.15	1.53	0.21	
CD4/CD45RO/CRTH2	0.07 - 2.97	1.06	0.11	1.13	0.11	1.07	0.15	1.22	0.18	
CD8/CRTH2	<2.43	3.67	1.19	1.72	0.35	1.45	0.40	2.07	0.67	
CD8/CD45RO/CRTH2	<1.45	1.76	0.58	0.72	0.20	0.47	0.12	1.09	0.46	
<b>B Cell Maturation and Subtypes</b>										
CD20/CD5	0.1 - 4.5	0.97	0.16	0.66	0.11	0.65	0.15	0.67	0.18	
CD20/CD27	0.4 - 5.4	1.91	0.26	2.19	0.31	2.23	0.40	1.95	0.54	
CD21 B-cells	73.2 - 95	89.17	0.92	57.27	3.43	53.80	4.66	63.54	5.40	
CD21 dim B-cells	3.7 - 21.1	8.35	0.56	34.03	2.95	35.48	3.85	29.90	4.87	
IgG B-cells	2.5 - 17.4	4.80	0.40	8.21	0.71	7.67	0.78	9.17	1.42	
IgA B-cells	1.5 - 7.3	6.61	0.62	5.55	0.55	5.83	0.86	4.82	0.63	
IgM B-cells	69.1 - 97.6	85.39	0.79	84.49	0.98	84.29	1.24	84.73	1.81	
IgD B-cells	69.0 - 97.6	85.17	1.08	77.97	1.39	77.42	1.54	78.48	2.81	
IgMCD27 B-cells	5.6 - 27.2	13.60	1.43	8.76	0.84	9.02	1.17	8.79	1.36	
<b>Dendritic Cell Monitoring</b>										
DC	0.04 - 0.5	0.17	0.02	0.13	0.03	0.09	0.02	0.19	0.06	
CD11d	32.6 - 86	60.17	3.03	60.89	4.22	50.91	5.82	72.42	5.44	
BDCA2	8.9 - 59.9	31.10	3.35	9.80	1.77	8.02	2.02	13.38	3.27	

Lymphocyte Monitoring	% CD3- Caspase 1		% CD3+ Caspase 1		% CD3+CD4 Caspase 1	
	Nigericin +	Nigericin -	Nigericin +	Nigericin -	Nigericin +	Nigericin -
Monocytes	<b>0.0478</b>	0.2366	<b>0.0036</b>	0.0535	<b>0.0071</b>	0.1902
Lymphocytes	0.1022	0.0938	0.4072	0.1261	0.6053	0.5053
CD3	0.2239	0.0794	0.892	0.9462	0.0991	0.4789
CD20	0.0798	<b>0.0024</b>	0.4962	0.0883	<b>0.2428</b>	0.2798
CD3-CD16+ or CD56+	0.2284	0.1597	0.0586	<b>0.0033</b>	0.2261	<b>0.0014</b>
%TBNK	0.1822	0.8014	0.0707	0.1595	0.2188	0.2105
CD3+CD16+ or CD56+	0.3994	0.2117	0.1702	0.0738	0.601	0.2402
<b>T Cell Monitoring and Activation</b>						
CD3+/CD4+	0.6769	0.6096	0.1232	0.3913	0.3922	0.4621
CD3+/CD8+	0.608	0.3932	0.3267	0.6269	0.4266	0.7698
CD3+/CD4-/CD8-	0.1454	0.1243	0.1001	<b>0.0158</b>	0.7973	<b>0.019</b>
CD3/alpha/beta	0.4105	0.1811	0.417	0.634	<b>0.0417</b>	0.2598
CC3/gamma-delta	<b>0.0141</b>	0.1792	<b>0.0216</b>	<b>0.0077</b>	0.7028	<b>0.0109</b>
DNT/alpha/beta	0.1929	0.5278	0.598	0.7579	0.9569	0.6647
DNT/gamma-delta	<b>0.0485</b>	0.1002	<b>0.0436</b>	<b>0.0039</b>	0.7021	<b>0.0048</b>
CD3+/CD8+/CD57+	0.1635	0.5568	0.0764	0.1449	0.6246	0.6792
CD3+/HLA-DR	0.0776	0.9094	0.2337	0.8529	0.4491	0.4745
CD3+/CD25	0.8961	0.9711	0.5885	0.2219	0.2188	0.5518
T4/T8 Ratio	0.4452	0.7438	0.1734	0.6016	0.5961	0.7592
<b>T Cell Memory</b>						
CD3/CD4/CD45RO	0.3395	0.8005	<b>0.0094</b>	0.2178	<b>0.0001</b>	0.1798
CD3/CD4/CD45RA	0.5221	0.9367	<b>0.0018</b>	0.0958	<b>0.004</b>	0.1213
CD3/CD8/CD45RO	<b>0.0242</b>	0.1725	0.0948	0.1103	0.5399	0.5101
CD3/CD8/CD45RA	0.0575	0.388	0.9182	0.3908	0.3846	0.4088
CD4/CRTH2	0.7054	0.1075	0.028	<b>0.0371</b>	0.0049	<b>0.0081</b>
CD4/CD45RO/CRTH2	0.6206	0.2372	<b>0.0173</b>	0.03	<b>0.0017</b>	<b>0.007</b>
CD8/CRTH2	0.6995	0.7309	0.7685	0.9211	0.672	0.963
CD8/CD45RO/CRTH2	0.5397	0.1153	0.8389	0.2586	0.5109	0.2389
<b>B Cell Maturation and Subtypes</b>						
CD20/CD5	0.36	0.6784	0.8324	0.2975	0.46	0.3127
CD20/CD27	0.2057	0.0008	0.9999	0.0648	0.0829	0.2098
CD21 B-cells	0.4523	0.5262	0.9629	0.8012	0.5335	0.6538
CD21 dim B-cells	0.5599	0.7177	0.8625	0.813	0.6931	0.9081
IgG B-cells	0.355	<b>0.0271</b>	0.3089	0.0782	0.3498	0.107
IgA B-cells	0.7526	0.3071	0.5451	0.1946	0.8895	0.3013
IgM B-cells	0.9812	0.2845	0.5311	0.1143	0.8302	0.1667
IgD B-cells	0.4499	0.4946	0.5885	0.2219	0.1677	0.1857
IgM/CD27 B-cells	0.0961	<b>0.0342</b>	0.183	0.0677	0.9072	0.1732
<b>Dendritic Cell Monitoring</b>						
DC	0.3404	0.5682	<b>0.2457</b>	<b>0.0188</b>	0.9358	0.1098
CD11d	0.113	0.6528	<b>0.0007</b>	<b>0.5627</b>	<b>0.0196</b>	0.8607
BDCA2	0.687	<b>0.003</b>	0.27	<b>0.0051</b>	0.4543	<b>0.0187</b>

**Supplementary information on antibodies:**

The antibodies utilized from Thermo Fisher Scientific were CD56 SB436 [TULY56], CD45 eF506 [HI130], CD3 FITC [SK7], CD16 PE [B73.1], CD8 PerCP-eF710 [SK1] CD14 PE-CY7 [61D3], CD4 APC [SK-3], CD20 APC-eF780 [2H7] CD25 EF450 [CD25-4E3], CD57 FITC [TBo1], TCR $\gamma$ - $\delta$  PE [B1.1], CD4 PerCP-eF710 [SK-3], CD3 PE-CY7 [SK7], TCR  $\alpha$  $\beta$  APC [IP26], HLA-DR AF700 [LN3], CD8 APC-eF780 [SL1], IgD SB436 [IA6-2], IgA FC Secondary Antibody FITC, IgG FC Secondary Antibody PE, IgM PerCP-eF710 [SA-DA4], CD19 PE-CY7 [SJ25C1], CD27 APC [O323], CD5 FITC [UCHT2], CD21 PE [HB5], CD27 PerCP-eF710 [O323], CD45RA FITC [HI100], CD45RO PerCP-eF710 [UCHL1], CD294 APC [BM16], CD4 AF700 [RPA-T4], CD3 FITC [SK7], CD14 FITC [61D3], CD16 FITC [3G8], CD19 FITC [SJ25-C1], CD20 FITC [2H7], CD56 FITC [TULY56], CD34 FITC [4H11], CD11c PE [3.9], HLA-DR PerCP-EF710 [L243], CD303a APC [201A], CD4 SB600 [SK-3], CD45RA FITC [HI100], CD3 PE-CY7 [SK7], CD8 AF700 [SK1], CCR5 APC [NP-6G4], CD25 APC [BC96], CD317 PE [26F8], IL-6 PE-CY7 [MQ2-13A5], MIP1- $\beta$  APC [FL34Z3L].

The antibodies utilized from BD Bioscience were HLADR BV480 [G46-6], CD38 PerCP-CY5.5 [HIT2], CD28 APC [CD28.2], CD45 APC H7 [2D1], CD278 BV421 [DX29], CXCR5 PerCP-CY5.5 [RF8B2], CD127 BV480 [HIL-7R-M21], CD45RO PerCP-CY5.5 [UCHL1], CD20 APC-H7 [2H7], CD11b BV421 [ICRF44], CD16 FITC [NKP15], MIP1- $\alpha$  PE [11A3], HLA-DR PerPC-Cy5.5 [L243]. TNF- $\alpha$  BV421 [Mab11] was from Biolegend (San Diego, CA).